SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (10315)3/22/2011 7:33:36 AM
From: rkrw1 Recommendation  Read Replies (1) of 10345
 
I would call it a price creep. First Tysabri priced well above their competition but they justified it, better results deserved a premium price. So the old MS mainstays then take the price gap and in turn raise their prices. Now an oral pill is approved, low cost of goods, instead of pricing at a discount, they price at a huge premium to Tysabri. And yet again everyone else takes the opportunity to narrow the gap. The extreme pricing elasticity of drugs continues to surprise me.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News